This fall, researchers and oncologists at Providence Cancer Institute are scheduled to or have contributed more than 20 presentations across international oncology and pathology conferences. This type of engagement reflects a broad effort to translate scientific insight into better cancer detection, treatment selection, immune monitoring and supportive care.
Let’s dive in.
At ESMO Congress 2026, October 23-27, in Madrid, Spain, Brian Piening, Ph.D., presented real-world findings on the molecular profile, treatment patterns and outcomes of HER2-mutant disease using the AACR Project GENIE Registry.
“A comprehensive AI-enabled pre-screening panel for non-small cell lung carcinoma using computational pathology applied to H&E whole slide images (WSI),” co-authored by Dr. Piening and Carlo Bifulco, M.D., was presented by Amy L. Cummings, M.D., Ph.D., of UCLA. Dr. Bifulco was unable to attend the meeting because of other speaking commitments, including a keynote presentation in Singapore. He contributed to the research through Providence Genomics.
Rachel Sanborn, M.D., is lead author on a phase I study presented on October. 23. The study title is "Phase 1, first-in-human study of MGC026, a B7-H3–targeted antibody-drug conjugate (ADC) in advanced solid tumors."
Also at ESMO, David B. Page, M.D., presented with Dr. Healther McArthur, on the phase II neoHIP trial, which suggests that hormone receptor status, PD-L1 expression and stromal tumor-infiltrating lymphocytes may help identify patients with early-stage HER2-positive breast cancer who are most likely to benefit from pembrolizumab.
On October 30, Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed), will serve as a panelist at the Cancer Care at the Crossroads meeting in New York.
SITC 2026: Phoenix, AZ
The Society for Immunotherapy of Cancer (SITC) annual meeting represents the largest group, with nine presentations.
On November 6:
-
- Jessica Linak will give a poster presentation on spatial immune exclusion across the lobular breast cancer continuum;
- Tahereh Ziglari will give a poster presentation titled “T regulatory cells as a mechanistic driver and predictive biomarker of response to aPD-1+aLAG-3 therapy;”
- Elizabeth Gould will present on exploring a flexible framework for implementing high-parameter spectral flow cytometry assays in clinical settings; and
- Duncan Hindmarch will present on a study investigating whether CD4-low, CD8-high T cells recognize and respond to tumor cells in renal cell carcinoma.
Also, Colin Thalhofer (Agonox, Inc.) will present, “Scientific and Clinical Updates: CD39⁺CD103⁺CD8⁺ Selected TIL (AGX-148) Can be Rescued from Exhaustion and Regress Human Tumors.”
Four presentations are scheduled for November 7:
-
- Alex Bartlett will give an oral presentation titled, “Single-Assay Mapping of Antibody Drug Conjugate Target Co-expression and Immune Contexture in Pan-Cancer Tissue Microarrays with Multiplex Immunofluorescence.”
- Alex will also present phase II findings in a poster presentation: “Lymphatic-sparing neoadjuvant SABR and pembrolizumab (Neo-ImmunoSABR) in HPV-negative HNSCC.”
- Racheli Ben-Shimol will present “Same-slide proximity ligation and multiplex immunofluorescence uncovers cell-type-specific PD-1/PD-L1 checkpoint dynamics in melanoma sentinel lymph nodes,” in a poster presentation.
- Kengo Tanigawa will present a study on tumor-reactive T cells and mature natural killer cells in responders to high-dose interleukin-2.
Seattle to San Antonio
At the Association for Molecular Pathology meeting in Seattle, Alexa Dowdell will present work on integrating longitudinal circulating tumor DNA sequencing with quantitative ESR1 mutation analysis to support molecular monitoring in metastatic breast cancer. The study is scheduled as a poster presentation on November 13 and as an oral platform presentation on November 14.
At the Academy of Oncology Nurse & Patient Navigators conference in Houston, Michelle Ferretti, MSW, LCSW, OSW-C, will give an oral presentation on implementing new national guidelines for integrative approaches to cancer-related symptoms on November 12. Krista Nelson, MSW, LCSW, OSW-C, FAOSW, FAPOS, FACCC, is on the advisory leadership board and will present on crisis navigation.
Brendan Curti, M.D., will present “Updates in Melanoma: Beyond Checkpoints and BRAF Targeted Therapy,” at the Advanced Practice Providers Oncology Summit in Portland on November 16.
David B. Page, M.D., is co-author of two papers being presented at the San Antonio Breast Cancer Symposium, December 8-11:
- "Inter-observer stromal TIL scoring variability and prediction of pembrolizumab benefit in early HER2+ breast cancer: biomarker analysis of the phase II neoHIP trial"
- "Real-world cardiotoxicity surveillance patterns, incidence, and clinical outcomes among early-stage breast cancer patients receiving curative-intent anti-HER2 therapy"
Natasha Edwin, M.D., will present findings from a survey of physicians and patients on use of bispecific antibodies and CAR-T cells in myeloma at ASH 2026, December 12-15.
Early fall presentations
On October 13, Dr. Bryan Bell gave, “Perioperative Immunotherapy for Head and Neck Cancer,” at the Grand Rounds at the Chinese University of Hong Kong.
In October 3, Christopher Darus, M.D., presented a study at the International Gynecologic Cancer Society conference in Montréal that examines outcomes with chemotherapy alone among U.S. patients with advanced or recurrent endometrial cancer. The study compared results by tumor mismatch repair status.
On September 16, Dr. Bryan Bell gave the Presidential Lecture “Perioperative Immunotherapy: Surgeons at the Vanguard of Revolution,” at the European Association for Cranio-Maxillofacial Surgery Congress in Athens, Greece.
Also, Dr. Bryan Bell gave “The Role of Neoadjuvant Immunotherapy in Advanced Resectable Oral/Head and Neck Cancer,” at the American Association of Oral and Maxillofacial Surgeons meeting in Seattle, on September 30.
Combined, these presentations show the breadth of work underway across the cancer care continuum at Providence Cancer Institute. Find out more about our research, advanced treatments and personalized care, here.
Related news
A new option for hard-to-treat ovarian cancer is being evaluated
Dark genome, bright outcome: A first-of-its-kind trial gives Del Abbott a second chance
New study evaluates a medication for NSCLC with the KRAS G12C mutation
